NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NexImmune, Inc.

NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology.  NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities.  For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond. 

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	1.23 -	0.78 36.48%	0.25 67.54%	4.05 1,492.52%	1.44 64.48%	3.05 111.93%
company equity multiplier	1.31 -	1.29 1.18%	-0.72 155.49%	1.09 251.51%	1.33 22.66%	2.45 83.68%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	0.97 -	0.98 1.51%	1.07 9.00%	0.96 10.87%	0.99 3.67%	0.98 1.00%
effective tax rate	-0.03 -	0.01 137.67%	-0.06 594.18%	-0.02 72.07%	9.23 55,747.96%
enterprise value multiple	-18.95 -	-15.56 17.85%	-18.98 21.95%	-1.20 93.69%	0.44 137.10%	0.02 94.51%
fixed asset turnover
free cash flow per share	-1.23 -	-1.60 29.53%	-1.38 13.69%	-2.38 72.86%	-2.18 8.58%	-30.00 1,276.01%
gross profit margin
interest coverage			-16.55 -	-58.82 255.44%	0.11 100.19%
inventory turnover
long term debt to capitalization					0.01 -
net income per ebt	1 -	0.99 1.20%	1.06 7.22%	1.02 4.04%	-8.23 909.20%	1 112.16%
net profit margin
operating cash flow per share	-1.14 -	-1.50 31.98%	-1.34 11.07%	-2.27 69.80%	-2.13 6.19%	-29.95 1,307.56%
operating profit margin
payables turnover
pretax profit margin
price fair value	22.89 -	30.86 34.79%	-31.78 203.00%	1.11 103.50%	0.18 83.70%	0.66 266.60%
receivables turnover
return on assets	-0.91 -	-1.48 63.07%	-2.80 89.19%	-0.57 79.70%	11.94 2,200.72%	-3.76 131.52%
return on capital employed	-1.19 -	-1.95 64.30%	1.77 190.68%	-0.64 135.88%	-1.93 203.37%	-9.39 387.39%
return on equity	-1.19 -	-1.91 61.15%	2.01 204.98%	-0.62 130.76%	15.92 2,676.78%	-9.22 157.89%
total debt to capitalization			5.68 -		0.03 -	0.02 37.47%

COM:NEXIMMUNE

NexImmune

Last Close

0.30

22/11 20:00

Market Cap

3.17M

Beta: -

Volume Today

1.67K

Avg: -

Preview